This report describes seroconversion of hepatitis B surface antigen (HBsAg) in a patient with marked iron overload caused by chronic hepatitis B (CHB) after receiving iron chelation therapy and discusses the role of iron chelation therapy in CHB.Patient concerns:
Increased serum ferritin level for 2 months.Diagnosis:
Secondary iron overload and CHB.Intervention:
To relieve iron load of the body, the patient underwent regular phlebotomy therapy and deferoxamine (DFO) therapy. During the therapy, serum ferritin and hepatitis B virus (HBV) were monitored and the iron concentration of the liver and heart were followed by T2* of magnetic resonance imaging (MRI) scan.Outcomes:
Serum ferritin gradually decreased. Approximately 1 year after the therapy, HBsAg turned persistently negative.Lessons:
Iron chelation therapy may attenuate HBV infection.